LANSING, Mich. — Michigan Attorney General Dana Nessel announced Tuesday that the state has joined a multistate coalition reaching settlement agreements with two pharmaceutical companies as part of ongoing antitrust litigation involving generic prescription drugs.

The settlements, reached with Lannett Company and Bausch Health, total $17.85 million, according to the attorney general’s office. The agreements resolve allegations brought by state attorneys general that the companies participated in coordinated conduct to raise prices and limit competition for certain generic drugs.

As part of the settlements, both companies agreed to cooperate with states in ongoing litigation involving other corporate and individual defendants and to implement internal compliance measures related to antitrust law, according to the coalition.

The settlements follow earlier agreements reached with Apotex and Heritage Pharmaceuticals, which totaled $49.1 million. States are preparing for the first trial in the broader litigation, which is scheduled to take place in Hartford, Connecticut, in late 2026.

State officials said consumers who purchased generic prescription drugs manufactured by Lannett or Bausch between May 2009 and December 2019 may be eligible for compensation through the settlement process. Information on eligibility has been made available through a toll-free hotline and a settlement website operated by the coalition.

In a separate action, Nessel also joined a coalition of 42 states and territories in filing a new antitrust lawsuit against Novartis and its subsidiary Sandoz. The complaint alleges that the companies participated in agreements with other manufacturers to fix prices, allocate markets, and coordinate bids for dozens of generic drugs.

The lawsuit further alleges that Novartis transferred assets and later spun off Sandoz in an effort to limit potential liability related to previously filed antitrust cases. Those allegations have not been adjudicated.

Michigan is a participant in three related multistate antitrust cases involving the generic drug industry. The cases collectively name dozens of pharmaceutical companies and individual executives and involve a range of generic medications, including topical and oral drugs that account for billions of dollars in annual sales nationwide.

According to court filings, the cases are based on evidence gathered through multi-year investigations, including documents, phone records, and cooperation from former industry executives. The defendants have denied wrongdoing in prior filings, and the cases remain pending.

States and territories participating in the Lannett and Bausch settlements include Illinois, Minnesota, Wisconsin, and most other U.S. jurisdictions. Michigan also joined numerous Midwest and national partners in filing the new complaint against Novartis and Sandoz.